UCL key partner in £14m cancer biotherapeutics research hub

Researchers at UCL will play a leading role in a new world class hub for cancer biotherapeutics, which has been launched by Cancer Research UK. The Cancer Research UK City of London Centre brings together world leading researchers from UCL, King's College London, Queen Mary University of London and the Francis Crick Institute. Cancer Research UK's significant £14 million investment in the Centre will enable London to become a global centre of excellence for biotherapeutics, a pioneering field of cancer research. Cancer patients over large parts of the capital, including some of the most deprived areas of the city, will have the opportunity to take part in pioneering research as part of their treatment. Around 14 million people, in London and other areas of the country, are covered by the NHS trusts within UCL Partners and Kings Health Partners, and will be set to have access to the very latest innovations in biological cancer therapies. Director of UCL Cancer Institute, Professor Tariq Enver, will lead the new Cancer Research UK City of London Centre.  "There have already been huge advances in biotherapeutics, many led from our researchers at UCL, and there's enormous potential to transform how we approach the hardest to treat cancers like brain tumours and lung cancer," he said. "Our ambition is for the Centre to stimulate further economic activity in biotechnology in London as new companies are formed, and industry partners move in to translate the most promising discoveries into marketable therapies.